IVD China last week: Thermo Fisher and Biomobio, Wondfo, Randox and Realbio, BD Medical

Thermo Fisher and Biomobio Sign Strategic Agreement in Spatial Imaging

Thermo Fisher Scientific and Biomobio have successfully concluded a strategic cooperation agreement for the EVOS S1000 spatial imaging system.

This partnership deepens Thermo Fisher’s commitment to life sciences innovation and provides Chinese research institutions with cutting-edge cell imaging technologies. The collaboration signifies a new phase of joint advancement in cell engineering and spatial biology, injecting momentum into frontier life sciences research and accelerating the development of next-generation imaging solutions.

Wondfo Biotech and CFRD Partner to Build a Health Bridge Between China and Nepal

Wondfo Biotech recently joined forces with the China Foundation for Rural Development (CFRD), local government authorities, and hospitals to successfully host a cross-border health camp in Kathmandu, Nepal. 

As part of China-Nepal health cooperation under the Belt and Road Initiative, the event delivered accessible medical services and facilitated knowledge exchange in community health development. The initiative benefited over 300 local residents and tourists, strengthening bilateral ties and laying the groundwork for continued collaboration in public health.

Randox and Realbio Forge Strategic Partnership in Quality Control

Randox has officially granted Realbio Group an OEM authorization certificate for quality control raw materials, marking a milestone in their strategic partnership. 

This collaboration will integrate Randox’s technical expertise with Realbio’s localized strengths to deliver tailored, high-performance quality control solutions. The partnership aims to advance standardization in China’s third-party quality control industry, enhancing laboratory testing accuracy and patient safety while setting new benchmarks in lab quality management.

BD Medical Accelerates Localized Production in China

BD Medical is set to launch localized production of its high-end BD FACSLyric™ flow cytometer in China this summer, following the receipt of its Chinese medical device registration certificate. 

This milestone marks BD’s first localized production of high-end flow cytometry systems in the country. The move expands BD’s manufacturing footprint in China and enhances local access to advanced diagnostic technologies, ushering in a new era for precision flow cytometry and lab automation nationwide.